AU2016353004B2 - Benzofuran derivatives for the treatment of CNS and other disorders - Google Patents

Benzofuran derivatives for the treatment of CNS and other disorders Download PDF

Info

Publication number
AU2016353004B2
AU2016353004B2 AU2016353004A AU2016353004A AU2016353004B2 AU 2016353004 B2 AU2016353004 B2 AU 2016353004B2 AU 2016353004 A AU2016353004 A AU 2016353004A AU 2016353004 A AU2016353004 A AU 2016353004A AU 2016353004 B2 AU2016353004 B2 AU 2016353004B2
Authority
AU
Australia
Prior art keywords
compound
benzofuran
acid
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016353004A
Other languages
English (en)
Other versions
AU2016353004A1 (en
Inventor
Srinivasa R. Cheruku
Jeffery A. Gladding
John C. Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambient Photonics Inc
Original Assignee
Ambient Photonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambient Photonics Inc filed Critical Ambient Photonics Inc
Publication of AU2016353004A1 publication Critical patent/AU2016353004A1/en
Assigned to Ambient Photonics, Inc. reassignment Ambient Photonics, Inc. Amend patent request/document other than specification (104) Assignors: Warner Babcock Institute for Green Chemistry
Application granted granted Critical
Publication of AU2016353004B2 publication Critical patent/AU2016353004B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2016353004A 2015-11-11 2016-11-10 Benzofuran derivatives for the treatment of CNS and other disorders Active AU2016353004B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253903P 2015-11-11 2015-11-11
US62/253,903 2015-11-11
PCT/US2016/061281 WO2017083488A1 (en) 2015-11-11 2016-11-10 Benzofuran derivatives for the treatment of cns and other disorders

Publications (2)

Publication Number Publication Date
AU2016353004A1 AU2016353004A1 (en) 2018-06-14
AU2016353004B2 true AU2016353004B2 (en) 2020-11-05

Family

ID=58695297

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016353004A Active AU2016353004B2 (en) 2015-11-11 2016-11-10 Benzofuran derivatives for the treatment of CNS and other disorders

Country Status (8)

Country Link
US (1) US10590100B2 (enExample)
EP (1) EP3374354B1 (enExample)
JP (1) JP6908805B2 (enExample)
CN (1) CN108699019B (enExample)
AU (1) AU2016353004B2 (enExample)
CA (1) CA3005212C (enExample)
IL (1) IL259674B (enExample)
WO (1) WO2017083488A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208712A1 (en) 2017-05-09 2018-11-15 Warner Babcock Insitute For Green Chemistry, Llc Stilbene and fused stilbene derivatives as solar cell dyes
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
EP3820465B1 (en) * 2018-07-10 2025-09-17 Ambient Photonics, Inc. Solar cell dyes for copper redox based dye sensitized solar cells and combinations thereof
TWI824012B (zh) * 2019-09-20 2023-12-01 美商安畢特光學公司 用於基於銅氧化還原的染料敏化太陽能電池的太陽能電池染料及其組合
WO2026055841A1 (zh) * 2024-09-11 2026-03-19 凯思凯迪(上海)医药科技股份有限公司 芳环并杂环类化合物、其制备方法和其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859350A (en) * 1971-08-13 1975-01-07 Hoechst Ag Benzofurane derivatives, process for their preparation and their use as optical brighteners
US4829067A (en) * 1986-12-02 1989-05-09 Tanabe Seiyaku Co., Ltd. Benzo-furan derivative
US5059621A (en) * 1984-09-19 1991-10-22 Centre International De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their thereapeutic and cosmetic use
WO2003051860A2 (en) * 2001-12-18 2003-06-26 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
US7473786B1 (en) * 2003-12-05 2009-01-06 University Of Massachusetts Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts
WO2013040528A1 (en) * 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1349453A (en) * 1918-01-09 1920-08-10 James H Hall Trap
US1348677A (en) * 1919-10-04 1920-08-03 Claude A Witter Process of manufacturing metallic shapes
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
CA2549736A1 (en) 2003-12-05 2005-06-23 The University Of North Carolina At Chapel Hill Cationic substituted benzofurans as antimicrobial agents
SE0403006D0 (sv) * 2004-12-09 2004-12-09 Biovitrum Ab New compounds
GB0505725D0 (en) * 2005-03-19 2005-04-27 Merck Sharp & Dohme Therapeutic agents
AU2007209981B2 (en) 2006-02-01 2011-11-24 Merck Sharp & Dohme Corp. Potassium channel inhibitors
TW200930369A (en) * 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US20090163586A1 (en) * 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
JP2012184224A (ja) * 2011-02-17 2012-09-27 Toho Univ Foundation アミロイドβタンパク質凝集阻害活性を有する化合物又はその薬理学的に許容し得る塩及びその製造方法、並びに、その用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
AU2013323198B2 (en) * 2012-09-28 2018-03-29 Srinivasa R. Cheruku Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859350A (en) * 1971-08-13 1975-01-07 Hoechst Ag Benzofurane derivatives, process for their preparation and their use as optical brighteners
US5059621A (en) * 1984-09-19 1991-10-22 Centre International De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their thereapeutic and cosmetic use
US4829067A (en) * 1986-12-02 1989-05-09 Tanabe Seiyaku Co., Ltd. Benzo-furan derivative
WO2003051860A2 (en) * 2001-12-18 2003-06-26 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
US7473786B1 (en) * 2003-12-05 2009-01-06 University Of Massachusetts Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts
WO2013040528A1 (en) * 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAI-LI LIU ET AL., "Biotransformation of p-coumaric acid....", HELVETICA CHIMICA ACTA., CHVERLAG HELVETICA CHIMICA ACTA, BASEL., (2007), vol. 90, ISSN 0018-019X, pages 1117 - 1132 *
OTTO DANN ET AL., "Synthesen antimikrobieller biskationischer 2-(Phenoxyphenyl)-indole und 1-Benzofurane", LIEBIGS ANNALEN DER CHEMIE, (1984), pages 409 - 425 *
STANISLAV A. BAKUNOV ET AL., JOURNAL OF MEDICINAL CHEMISTRY., USAMERICAN CHEMICAL SOCIETY. WASHINGTON., (2009-10-08), vol. 52, no. 18, ISSN 0022-2623, pages 5763 - 5767 *

Also Published As

Publication number Publication date
JP2019501875A (ja) 2019-01-24
IL259674B (en) 2021-07-29
US10590100B2 (en) 2020-03-17
EP3374354B1 (en) 2022-09-28
IL259674A (en) 2018-07-31
JP6908805B2 (ja) 2021-07-28
CN108699019A (zh) 2018-10-23
EP3374354A1 (en) 2018-09-19
CA3005212C (en) 2024-01-23
WO2017083488A1 (en) 2017-05-18
EP3374354A4 (en) 2019-07-17
AU2016353004A1 (en) 2018-06-14
CA3005212A1 (en) 2017-05-18
US20180346433A1 (en) 2018-12-06
CN108699019B (zh) 2022-05-10

Similar Documents

Publication Publication Date Title
TWI766882B (zh) 新穎化合物類
AU2016353004B2 (en) Benzofuran derivatives for the treatment of CNS and other disorders
JP6204975B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
US10512626B2 (en) Compositions for use in treating glioblastoma
ES2670601T9 (es) Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
CA3153531A1 (en) Cdk inhibitors and their use as pharmaceuticals
WO2019106434A1 (en) Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
CA2932870C (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
KR20220068224A (ko) Perk 억제 화합물
JP2016514129A (ja) カリウムイオンチャネル阻害剤としてのフタラジン
WO2021041970A1 (en) Perk inhibiting imidazolopyrazine compounds
EP3958867B1 (en) Small molecule bromodomain inhibitors and uses thereof
JP2025509830A (ja) 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用
US11286233B2 (en) Stilbene derivatives for the treatment of CNS and other disorders
US11701345B2 (en) Car activator agents for cyclophosphamide-based treatments of cancer
EP4501918A1 (en) 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient
AU2019251363A1 (en) Morpholine derivates as inhibitors of Vps34
WO2021178684A1 (en) Car and nrf2 dual activator agents for cyclophosphamide-based and doxorubicin-based treatments of cancer
KR20200085815A (ko) 과증식성 질병의 치료를 위한 카페인산 유도체
KR20260029377A (ko) 암 및 염증성 질환 치료에 사용하기 위한 이미다조[1,2-α]피리딘 화합물 및 그 화합물의 제조 방법
CA3094714C (en) Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
US20260028364A1 (en) Cationic chromenones and their use in oncology
CA3094714A1 (en) Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
HK40058838A (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AMBIENT PHOTONICS, INC.

Free format text: FORMER NAME(S): WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY

FGA Letters patent sealed or granted (standard patent)